RxDoctor Payments DataLook up a doctor →

Firas Zahr, MD

Cardiovascular Disease · Portland, ORNPI 1568637049

Payments from drug & device makers

$7,735,698in general payments, 2019–2025

Across 1,655 payments — averaging $4674.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$6M
  • Medtronic$1M
  • Philips North America LLC$492K
  • GE HealthCare$58K
  • Abbott$40K
  • Jenavalve Technology, Inc.$39K
  • plus $59K from 8 others
$68,963in research payments, 2019–2025

Across 20 payments — averaging $3448.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$69K

What the payments were for

  • Consulting fees$342,63542%
  • Speaking & faculty fees$137,78917%
  • Grants$2,9300%
  • Travel & lodging$286,56335%
  • Food & beverage$40,5325%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,735,698 in reported general payments places this provider in the 95th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$122,460
Medicare patients
181
Services billed
403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate34$509

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →